Get to know our clinical trials
Trial of Temocillin vs meropenem for the treatment of bacteremia caused by Enterobacteriaceae resistant to third generation cephalosporins.
THE MAIN OBJECTIVE OF THE STUDY IN WHICH HE IS PROPOSED TO PARTICIPATE IS TO PROVE WHETHER TEMOCILLIN IS AS EFFECTIVE AND SAFE AS CARBAPENEMS IN THIS TYPE OF INFECTIONS, I.E., TO DEMONSTRATE THAT ITS EFFECT IS AS BENEFICIAL AS CARBAPENEMS AND THAT IT DOES NOT PRODUCE MORE SIDE EFFECTS.
Technical Summary
- TEMOCILLIN VS MEROPENEM FOR THE TREATMENT OF THIRD-GENERATION CEPHALOSPORIN-RESISTANT ENTEROBACTERIACEAE BACTEREMIA: A RANDOMIZED, PRAGMATIC TRIAL.
- Code EudraCT: 2020-000064-39
- Protocol number: ASTARTÉ
- Promoter: FISEVI
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.